India's Bulk Drug Capital: How Hyderabad Became Central to India's Pharmaceutical Export Economy

During the COVID-19 pandemic, global attention turned briefly to India's pharmaceutical manufacturing capacity. The world needed vaccines, antivirals, and generic drugs at scale. Much of what it got came from Hyderabad.

Official data from Invest Telangana and NIPER Hyderabad (the National Institute of Pharmaceutical Education and Research) states that Hyderabad accounts for approximately 40% of India's total bulk drug production and 50% of India's bulk drug exports. More than 800 life sciences companies operate within the greater Hyderabad region.

What Bulk Drugs Are

A bulk drug — or active pharmaceutical ingredient (API) — is the biologically active molecule in a medicine. Paracetamol, amoxicillin, metformin: the raw molecules that make these work are bulk drugs. They are manufactured at scale through chemical synthesis or fermentation processes, then shipped to formulation plants worldwide, where they become tablets, capsules, or injectables.

India is the world's third-largest pharmaceutical manufacturer by volume and produces approximately 60,000 generic brands across 60 therapeutic categories. The API supply chain underpinning that output is heavily concentrated in Hyderabad.

How It Happened

Hyderabad's pharmaceutical concentration was built over three decades, from the liberalisation of the 1990s onward. Labour: Hyderabad's engineering and science colleges produced large numbers of chemical engineers and biochemists. Land and infrastructure: the Telangana government developed dedicated pharmaceutical zones — including the PHARMACITY cluster and Genome Valley — with shared utilities and regulatory infrastructure.

As bulk drug manufacturers clustered in Hyderabad, their suppliers followed. Raw material traders, packaging companies, contract research organisations, and regulatory affairs consultants all established Hyderabad operations, creating a self-reinforcing ecosystem.

The China Dependency Problem

In 2020, COVID-19 supply chain disruptions exposed a structural vulnerability: significant Indian dependence on China for key starting materials (KSMs) and chemical intermediates used in API synthesis. For certain APIs, a Chinese supply disruption directly threatened the ability to manufacture finished medicines.

The Government of India responded with a Production Linked Incentive (PLI) scheme for bulk drugs, with a total outlay of ₹6,940 crore. The scheme targets 53 KSMs and APIs where import dependence was highest, incentivising domestic production of each. Hyderabad's existing API manufacturers are among the primary beneficiaries.

Pharma City

The most ambitious project in Hyderabad's pharmaceutical story is the Hyderabad Pharma City, being developed by the Telangana State Industrial Infrastructure Corporation (TSIIC) at Mucherla in Ranga Reddy district, approximately 35 kilometres from the airport.

Planned across 19,000 acres, the project proposes shared infrastructure — effluent treatment plants, common utilities, internal logistics corridors — that small and mid-size API manufacturers typically cannot afford independently. Official Invest Telangana data describes:

• Estimated investment potential: ₹64,000 crore
• Annual export potential: ₹58,000 crore
• Projected direct employment: 1.5 lakh people
• Projected indirect employment: 5 lakh people

The Research Ecosystem

What distinguishes Hyderabad from other Indian pharmaceutical manufacturing centres is significant research infrastructure alongside the manufacturing base. NIPER Hyderabad provides postgraduate and doctoral education in pharmaceutical sciences, along with industry collaboration. IIT Hyderabad has active programmes in drug delivery. The Centre for Cellular and Molecular Biology (CCMB) is a national biological research institution based in the city.

This institutional concentration creates a talent pipeline that feeds the 800-plus life sciences companies — and, increasingly, the R&D centres of multinational pharmaceutical firms that have established Hyderabad operations for drug discovery and regulatory affairs work.

The Strategic Significance

India's ambition is to move up the pharmaceutical value chain: from bulk drug manufacturer to formulation leader to, eventually, drug discoverer. Hyderabad is the city where that ambition is most credibly grounded in existing industrial reality.

The manufacturing base is there. The research institutions are there. The talent pipeline is there. The question is whether the next phase of development — Pharma City, the PLI investments, the R&D centres — arrives fast enough and at sufficient scale to shift Hyderabad from bulk drug hub to full pharmaceutical ecosystem.